Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13489654 | 0.81 | HSD11B1 (0.51) | HSD11B1MALT1TRPV1PTPN11 | |
| SCHEMBL30417113 | 0.81 | HSD11B1 (0.51) | HSD11B1MALT1TRPV1PTPN11 | |
| SCHEMBL3210143 | 0.81 | HSD11B1 (0.51) | HSD11B1MALT1TRPV1PTPN11 | |
| SCHEMBL4635199 | 0.75 | HSD11B1 (0.46) | HSD11B1MALT1TRPV1PTPN11 | |
| SCHEMBL30511942 | 0.74 | DPP4 (0.46) | HSD11B1MALT1TRPV1 | |
| SCHEMBL30416835 | 0.74 | HSD11B1 (0.51) | HSD11B1TRPV1 | |
| SCHEMBL30416776 | 0.74 | HSD11B1 (0.51) | HSD11B1TRPV1 | |
| SCHEMBL20283136 | 0.74 | HSD11B1 (0.48) | HSD11B1MALT1TRPV1 | |
| SCHEMBL30417130 | 0.74 | HSD11B1 (0.45) | HSD11B1MALT1TRPV1 | |
| SCHEMBL7396450 | 0.74 | HSD11B1 (0.45) | HSD11B1MALT1TRPV1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153809-A1 | NOVEL AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009841-A1 | Novel amides useful for treating pain | OPRL1, OPRK1, FAAH2 | CHRNB2 231/4885CHRNA4 208/4885HSD11B1 2183/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | CHRNB2 352/4885CHRNA4 237/4885HSD11B1 4395/4885 |
| US-20070010557-A1 | Novel amides useful for treating pain | OPRL1, PDE6B, PDE6G | CHRNB2 2225/4885CHRNA4 1477/4885HSD11B1 3143/4885 |
| US-20080153809-A1 | NOVEL AMIDES USEFUL FOR TREATING PAIN | OPRL1, OPRK1, OPRD1 | CHRNB2 1414/4885CHRNA4 762/4885HSD11B1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.